anti-Coagulation Factor VIII (F8) Antikörper

F8 encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. Zusätzlich bieten wir Ihnen Factor VIII Kits (64) und Factor VIII Proteine (25) und viele weitere Produktgruppen zu diesem Protein an.

Alle Antikörper anzeigen Gen GeneID UniProt
F8 14069 Q06194
F8 2157 P00451
F8 302470  
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen

Top anti-Factor VIII Antikörper auf

Showing 10 out of 323 products:

Katalog Nr. Reaktivität Wirt Konjugat Applikation Bilder Menge Anbieter Lieferzeit Preis Details
Human Kaninchen Unkonjugiert WB 100 μg Anmelden zum Anzeigen 4 bis 6 Tage
Rind (Kuh) Kaninchen Unkonjugiert WB Host: Rabbit  Target Name: F8  Sample Tissue: 721_B Whole Cell  Lane A:  Primary Antibody Lane B:  Primary Antibody + Blocking Peptide Primary Antibody Concentration: 1 µg/mL Peptide Concentration: 2 µg/mL Lysate Quantity: 241 µg/laneGel Concentration: 2.12 % 100 μL Anmelden zum Anzeigen 2 bis 3 Tage
Human Kaninchen Unkonjugiert ICC, IF, IHC, IHC (p), WB Western Blot: Factor VIII antibody (S2194) [ABIN4493381] - in extracts from HuvEc cells. Immunocytochemistry/Immunofluorescence: Factor VIII Antibody [ABIN4493381] - Factor VIII antibody was tested 1:50 in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). Image objective 40x. 0.1 mg Anmelden zum Anzeigen 7 bis 9 Tage
Hund Kaninchen Unkonjugiert WB Western blot analysis of Factor VIII expression in HeLa (A), HepG2 (B) whole cell lysates. 200 μL Anmelden zum Anzeigen 13 bis 14 Tage
Human Kaninchen Unkonjugiert ELISA, ICC, IF, IHC, WB ABIN6266536 staining HuvEc cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Cat.# S0006), diluted at 1/600, was used as secondary antibody. Western blot analysis on HuvEc cell lysate using Factor VIII Antibody,The lane on the left is treated with the antigen-specific peptide. 100 μL Anmelden zum Anzeigen 11 bis 12 Tage
Human Maus Unkonjugiert ELISA Detection limit for recombinant GST tagged F8 is approximately 3ng/ml as a capture antibody. Proximity Ligation Analysis of protein-protein interactions between CALR and F8. HeLa cells were stained with anti-CALR rabbit purified polyclonal 1:1200 and anti-F8 mouse monoclonal antibody 1:50. Each red dot represents the detection of protein-protein interaction complex, and nuclei were counterstained with DAPI (blue). 100 μg Anmelden zum Anzeigen 8 bis 11 Tage
Human Kaninchen Unkonjugiert ELISA, WB Western blot analysis of extracts from HuvEc cells, using Factor VIII Antibody. The lane on the right is treated with the synthesized peptide. 100 μg Anmelden zum Anzeigen 2 bis 3 Tage
Human Maus Unkonjugiert ELISA, WB Figure 1: Western blot analysis using F8 mouse mAb against truncated Trx-F8 recombinant protein (1). Dilution: 1/500 - 1/2000 Figure 2: Immunohistochemical analysis of paraffin-embedded human Liver tissues using BHMT mouse mAb Dilution: 1:200~~1000 100 μL Anmelden zum Anzeigen 10 bis 11 Tage
Hund Kaninchen Unkonjugiert IF (p), IHC (p) Formalin-fixed and paraffin embedded rat tibia tissue labeled with Anti-Factor VIII (FVIII) Polyclonal Antibody (ABIN668601) , Unconjugated at 1:300, followed by conjugation to the secondary antibody and DAB staining Formalin-fixed : Mouse C57 cells labeled with Anti- Factor VIII (FVIII) Polyclonal Antibody (ABIN668601) , Unconjugated at 1:300, followed by conjugation to the secondary antibody was Goat Anti-Rabbit IgG, PE conjugated  at 1:200 for 40 minutes at 37 °C DAPI (5 µg/mL, blue) was used to stain the cell nuclei 100 μL Anmelden zum Anzeigen 3 bis 7 Tage
Human Kaninchen Unkonjugiert ELISA, IHC, WB 100 μL Anmelden zum Anzeigen 16 Days

Am meisten referenzierte anti-Factor VIII Antikörper

  1. Human Polyclonal Factor VIII Primary Antibody für WB - ABIN3042924 : Wu, Chen, Guo, He, Hu: Effects of transforming growth factor-?2 on myocilin expression and secretion in human primary cultured trabecular meshwork cells. in International journal of clinical and experimental pathology 2014 (PubMed)
    Show all 15 Pubmed References

  2. Dog (Canine) Polyclonal Factor VIII Primary Antibody für IF (p), IHC (p) - ABIN668601 : Yu, Zhang, Jiang, Wang, Zhang: Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction. in Molecular medicine reports 2015 (PubMed)
    Show all 3 Pubmed References

  3. Human Polyclonal Factor VIII Primary Antibody für IF (p), IHC (p) - ABIN872493 : Tang, Liu, Dong, Li, Li, Hou, Zheng, Lin, Ren: Protective Effect of Kaempferol on LPS plus ATP-Induced Inflammatory Response in Cardiac Fibroblasts. in Inflammation 2014 (PubMed)
    Show all 2 Pubmed References

  4. Human Monoclonal Factor VIII Primary Antibody für ELISA, WB - ABIN969123 : Shovlin, Sulaiman, Govani, Jackson, Begbie: Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. in Thrombosis and haemostasis 2007 (PubMed)
    Show all 2 Pubmed References

  5. Human Polyclonal Factor VIII Primary Antibody für IF (cc), IF (p) - ABIN728000 : Zhou, Zhu, Zou, Wang: Changes in number and biological function of endothelial progenitor cells in hypertension disorder complicating pregnancy. in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 2008 (PubMed)
    Show all 2 Pubmed References

  6. Human Polyclonal Factor VIII Primary Antibody für ICC, IF - ABIN449338 : Zhu, Liu, Miao, Qu, Chi: Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors. in Science China. Life sciences 2012 (PubMed)
    Show all 2 Pubmed References

  7. Human Monoclonal Factor VIII Primary Antibody für ELISA, WB - ABIN966113 : Venceslá, Corral-Rodríguez, Baena, Cornet, Domènech, Baiget, Fuentes-Prior, Tizzano: Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites. in Blood 2008 (PubMed)
    Show all 2 Pubmed References

Weitere Antikörper gegen Factor VIII Interaktionspartner

Zebrafish Coagulation Factor VIII (F8) Interaktionspartner

  1. gene is flanked by factor VII and factor X genes; gene encodes a protein homologous to factor VII, but lacks critical residues for factor VII activity; functions as an inhibitor of blood coagulation in biochemical assays using zebrafish or human plasmas

Mouse (Murine) Coagulation Factor VIII (F8) Interaktionspartner

  1. Haemophilic animals (F8(-/-) mice) fed a high fat/fructose diet are highly prone to hepatic steatosis and thrombocytopenia.

  2. CD32 blockade suppresses the FVIII-specific recall response by two ways: i) increasing apoptosis of FVIII-specific memory B-cells and ii) disturbing FVIII-specific T cell response by modulating presentation of rhFVIII to CD4(+) T cells.

  3. Type 2N von Willebrand disease variants were associated with decreased VWF secretion and impaired factor VIII binding/stability.

  4. Cytokine release was quantified from FVIII(-/-) splenocytes restimulated with FVIII in the absence or presence of different anti-FcgammaRIIB (CD32) Antibodies (anti-CD32 mAbs) over 6 days.

  5. results revealed localized vascular expression of FVIII and von Willebrand factor and identified lymphatic endothelial cell as a major cellular source of FVIII in extrahepatic tissues.

  6. the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor masks the reducing effect of mutations in the C domains on factor VIII immunogenicity.

  7. Describe a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.

  8. data demonstrate that infusion of platelets containing FVIII triggers neither primary nor memory anti-FVIII immune response in FVIII(null) mice

  9. Both platelet-VWF and plasma-VWF are required for optimal platelet-derived FVIII gene therapy for hemophilia A in the presence of inhibitors.

  10. These data support the investigation of FVIII orthologs as treatment modalities in both the congenital and acquired FVIII inhibitor settings.

  11. Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.

  12. Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors.

  13. This study demonstrated that FVIIIa interacts with Low-density lipoprotein receptor-related protein 1 cluster III.

  14. a fragment containing only approximately 20% of the VWF sequence is sufficient to support FVIII stability in vivo

  15. Endothelial cells from multiple, but not all, tissues contribute to the plasma FVIII pool in the mouse.

  16. Endothelial cells are the predominant, and possibly exclusive, source of plasma FVIII.

  17. Micro-computed tomography analysis of distal tibia metaphyses also revealed for the first time a major impact of the FVIII/thrombin/PAR1 axis on the dynamic bone structure, showing reduced bone.

  18. Findings indicate that improving protein trans-splicing by inter-chain disulfide bonding is a promising approach for increasing the efficacy of dual-vector based FVIII gene transfer.

  19. Acute elevations in FVIII levels result in a non-linear thrombogenic effect, with non-significant increases in thrombogenic risk. Prolonged elevation of plasma FVIII did not further increase the thrombogenic potential of elevated FVIII levels.

  20. Transient B cell depletion and even more so use of a codon-optimized FVIII sequence in hepatic gene transfer represent promising strategies to avoid inhibitor formation and promote tolerance in gene therapy for hemophilia A.

Human Coagulation Factor VIII (F8) Interaktionspartner

  1. Differential impacts of ectopic N-glycosylation on FVIII folding, trafficking and activity, which highlight complex disease-causing mechanisms of FVIII missense mutations.

  2. This study describes an original pathological mechanism by which a small intronic deletion in F8 leads to Alu exonization.

  3. A common polymorphism decreases LRP1 mRNA stability and is associated with increased plasma factor VIII levels

  4. F8 and F9 gene variants result from a founder effect in two large French haemophilia cohorts

  5. our results demonstrate that the N-glycosylation sequon in the A2 domain is located in a structural element that is critically required for proper folding and conformation of FVIII.

  6. The aim of this study was to determine the F8 mutations in severe HA (sHA) patients and female carriers

  7. Human FVIII gene transfer without in vivo selection of manipulated cells can introduce immune tolerance in hemophilia A mice and this immune tolerance is CD4(+) T cell mediated.

  8. In Factor VIII, 41 mutations were identified, 19 of which were novel and 80% (44/55) of the pathogenic mutations fell into the categories of missense, nonsense(16.36%), frameshift (14.55%), and splice (5.45%) mutations.

  9. High dose of rhFVIII induces apoptosis in FVIII-specific memory B-cells but does not influence FVIII-specific T cell response.

  10. the potential role of FXIII-A in wound healing, as a field with long-term therapeutic implications, is also discussed

  11. Case Report: complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis in proband's mother.

  12. Report a diagnostic algorithm that can reliably identify pathogenic variants of factor 8/9 and von Willebrand factor and diagnose patients with hemophilia A, hemophilia B or von Willebrand disease.

  13. Each hFVIII vector was administered to FVIII knockout (KO) mice at a dose of 10(10) genome copies (GC) per mouse. Criteria for distinguishing the performance of the different enhancer/promoter combinations were established prior to the initiation of the studies.

  14. Relevance of ethnic differences in factor XIII activity on laboratory reference ranges.

  15. analysis of co-existing variants in both F8 and PTGS-1 genes in a three-generation pedigree of hemophilia A

  16. Potential mutations of the F8 gene were analyzed.

  17. FVIII endocytosis is driven by interaction with LRP1

  18. A coagulation initiating pathway is revealed in which the TF-FVIIa-nascent FXa complex activates FVIII apart from thrombin feedback.

  19. An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII by thrombin has been presented.

  20. Of special importance is the sequential formation of disulfide bonds with different functions in structural support of VWF multimers, which are packaged, stored and further processed after secretion. Here, all these processes are being reviewed in detail including background information on the occurring biochemical reactions. [review]

Pig (Porcine) Coagulation Factor VIII (F8) Interaktionspartner

  1. It was concluded that VEGF and factor VIII are important growth factors associated with fetal development in pigs and are identified in all uterine segments.

  2. Report Factor VIII organisation on nanodiscs with different lipid composition.

  3. thrombin stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII and by receptor-mediated up-regulation of factor XIII synthesis

  4. cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant

Cow (Bovine) Coagulation Factor VIII (F8) Interaktionspartner

  1. two factor VIII missense mutations are associated with a mild form of haemophilia A in German Fleckvieh cattle

  2. Factor VIIIc is responsible for tissue invasion during tumor progression.

  3. A missense mutation (p.Leu2153His) of the factor VIII gene causes cattle haemophilia A.

Factor VIII (F8) Antigen-Profil

Protein Überblick

This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.

Genbezeichner und Symbole assoziert mit F8

  • coagulation factor VIIi (f7i) Antikörper
  • coagulation factor VIII (F8) Antikörper
  • coagulation factor VIII, procoagulant component (F8) Antikörper
  • AHF Antikörper
  • Cf-8 Antikörper
  • Cf8 Antikörper
  • DXS1253E Antikörper
  • F8B Antikörper
  • F8C Antikörper
  • fb61d02 Antikörper
  • FVIII Antikörper
  • HEMA Antikörper
  • wu:fb61d02 Antikörper

Bezeichner auf Proteinebene für F8

Factor VIII , procoagulant component , antihemophilic factor , coagulation factor VIII , coagulation factor VIIIc , factor VIII F8B , coagulation factor VIII, procoagulant component (hemophilia A) , factor VIII , coagulation co-factor

282671 Danio rerio
14069 Mus musculus
2157 Homo sapiens
397339 Sus scrofa
403875 Canis lupus familiaris
100271720 Bos taurus
100303761 Oryctolagus cuniculus
302470 Rattus norvegicus
100359363 Ovis aries
422199 Gallus gallus
Ausgewählte Anbieter für anti-Factor VIII (F8) Antikörper
Haben Sie etwas anderes gesucht?